10:49 AM EDT, 04/30/2025 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Wednesday said it had presented a poster detailing new pre-clinical data from MDNA113, its first candidate from the BiSKIT platform, at the Annual Meeting of the American Association for Cancer Research (AACR) in Chicago.

The program "continues to generate encouraging pre-clinical data that underscores its potential as a first-in-class immunotherapy for immunologically cold tumors, said Chief Executive Fahar Merchant.

"Commercial interest for bi-specific anti-PD-1 therapies is gaining momentum, with several recent transactions validating this emerging class of immunotherapies with the potential to offer new hope to millions of cancer patients worldwide," Merchant added.

The company's shares were last seen down $0.04, to $1.06, on the Toronto Stock Exchange, amid big losses for the broader market.

Price: 1.06, Change: -0.04, Percent Change: -3.64